Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Christiaan Dolk"'
Publikováno v:
Expert Review of Vaccines, Vol 23, Iss 1, Pp 312-323 (2024)
ABSTRACTBackground A bivalent human papillomavirus vaccine (2vHPV) is currently used in the Netherlands; a nonavalent vaccine (9vHPV) is also licensed.Research design and methods We compared the public health and economic benefits of 2vHPV- and 9vHPV
Externí odkaz:
https://doaj.org/article/26b07d71c74e4e81b18cd339c4b576d4
Autor:
Samira Toghanian, John Moshtaghi-Svensson, Maria Papageorgiou, Kristin Kittelsen, Christiaan Dolk, Markus Hultstrand, Stina Salomonsson
Publikováno v:
Journal of Health Economics and Outcomes Research (2022)
**Background:** The prioritization of public funds in an equitable and ethically sound manner along with efficient budget allocation are key challenges for governments and budget holders. Following the introduction of generics/biosimilars, the potent
Externí odkaz:
https://doaj.org/article/d3f26483c73547b481f3001792542ab7
Autor:
Christiaan Dolk, Giedre Gefenaite, Diane Gross, Adriana Pistol, Odette Popovici, Mark Jit, Daniel Ciurea, Rodica Popescu
Publikováno v:
Influenza and other respiratory viruses, 12(1), 183-192. Wiley
Influenza and Other Respiratory Viruses
Influenza and Other Respiratory Viruses
BACKGROUND: Influenza is responsible for substantial morbidity and mortality, but there is limited information on reliable disease burden estimates, especially from middle-income countries in the WHO European Region.OBJECTIVES: To estimate the incide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec3f25f361ebf4c2b84dda916f57586c
https://research.rug.nl/en/publications/d77045e4-b8c7-41cb-b2cc-bc7009aa3482
https://research.rug.nl/en/publications/d77045e4-b8c7-41cb-b2cc-bc7009aa3482
Autor:
Ilse Van Vlaenderen, Ruprecht Schmidt-Ott, Anastassia Anastassopoulou, Markus Schwehm, Martin Eichner, Laure-Anne Van Bellinghen, Robert Welte, Christiaan Dolk, Barbara Poulsen Nautrup, Maarten J. Postma
Publikováno v:
Pharmacoeconomics
Pharmacoeconomics, 34(12), 1299-1308. ADIS INT LTD
Pharmacoeconomics, 34(12), 1299-1308. ADIS INT LTD
Background Seasonal influenza infection is primarily caused by circulation of two influenza A strain subtypes and strains from two B lineages that vary each year. Trivalent influenza vaccine (TIV) contains only one of the two B-lineage strains, resul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c281edb915e24539b83584cb6a6cc19
https://pubmed.ncbi.nlm.nih.gov/27647004
https://pubmed.ncbi.nlm.nih.gov/27647004
Publikováno v:
Value in Health, 17(7), A658-A659. ELSEVIER SCIENCE INC
Objectives: To identify differences in the recommendations for targeted cancer therapies (TCT) in three distinctive European health care systems: Serbian, Scottish and Dutch, and to examine the role of cost effectiveness analyses (CEA) in such recomm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03324eda5c2af1c73c04219702ed6eff
https://pubmed.ncbi.nlm.nih.gov/27202387
https://pubmed.ncbi.nlm.nih.gov/27202387
Publikováno v:
Clinical Therapeutics, 37(2), 474-480. Elsevier
PURPOSE: Targeted cancer therapies (TCTs) are drugs that specifically act on molecular targets within the cancer cell, causing its regression and/or destruction. Although TCTs offer clinically important gains in survival in one of the most challengin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7e662c4a066b4930803e31438814481
https://pubmed.ncbi.nlm.nih.gov/25638534
https://pubmed.ncbi.nlm.nih.gov/25638534